In 2018, in preparation of FDA submission, Hemanext completed a clinical study for the Hemanext ONE® RBC Processing and Storage System.
Recent Posts
- Hemanext Inc. Announces Completion of Post-Market Cancer and Burn Safety Study
- AABB Science Innovation Forum Nov 2023
- Hemanext Inc. Announces a Significant Milestone with FDA Marketing Authorization for Hemanext ONE®
- Hemanext Announces Founder Martin Cannon’s Retirement, Appoints Andrew Dunham as CEO, and Raises Funding for Growth
- Hemanext Continues European Rollout of Hemanext ONE® RBC Processing and Storage System